The role of ERT/HRT

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 3, 2002, Pages 371-381

  Samsioe, Göran ^a,b  

^a Department of Gynaecological Endocrinology ^*  (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Continuous combined; ERT; HRT; Transdermal

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; CIMETIDINE; CYPROTERONE; DYDROGESTERONE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE; NORETHISTERONE; RALOXIFENE; TIBOLONE; TRANQUILIZER; TRIMEGESTONE; PROGESTERONE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALZHEIMER DISEASE; BLEEDING; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG METABOLISM; ENDOMETRIUM CANCER; ESTROGEN THERAPY; GASTROINTESTINAL DISEASE; HORMONE DEFICIENCY; HUMAN; HYSTERECTOMY; LIVER DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; MIGRAINE; MONOTHERAPY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; AGED; DRUG ADMINISTRATION; FEMALE; INTRADERMAL DRUG ADMINISTRATION; LIVER; MENORRHAGIA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIVER; MENORRHAGIA; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0036593950     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0286     Document Type: Article

References (19)

1. Stadberg E, Milsom I & Mattsson LÅ. A Swedish population-based study. Women's attitudes and knowledge about the climacteric period and its treatment. Maturitas 1997; 27: 109-116.
2. Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstetricia et Gynecologica Scandinavica 1993; 157 (supplement): 1-26.
3. Mattsson LÅ, Bohnet HG, Gredmark T et al. Continuous combined hormone replacement therapy: randomized comparisons of transdermal and oral preparations. Obstetrics and Gynecology 1999; 94: 61-65.
4. Barnes RB & Levrant SG. Pharmacology of estrogens. In Lobo RA (ed.) Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 2nd edn, pp 95-104. Philadelphia: Lippincott Williams & Wilkins, 1999.
5. Lobo RA. Clinical aspects of hormonal replacement. In Lobo RA (ed.) Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 2nd edn, pp 125-139. Philadelphia: Lippincott Williams & Wilkins, 1999.
6. Jensen J & Christiansen C. Effect of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. American Journal of Obstetrics and Gynecology 1988; 159: 820-825.
7. Geisler J, Omsjö IH, Helle SI et al. Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy; influence of route of administration and cigarette smoking. Journal of Endocrinology 1999; 162: 265-270.
8. Dahlgren E, Crona N, Janson PO & Samsioe G. Oral replacement with estradiol-cycloctyl acetate: A new estradiol analogue. Effects on serum lipids, proteins, gonadotrophins, estrogens and uterine endometrial morphology. Gynecological and Obstetric Investigation 1985; 20: 84-90.
9. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equal. American Journal of Obstetrics and Gynecology 2001; 184: 255-263.
10. Consensus committee. Effects of menopause and estrogen replacement therapy or hormonal replacement therapy in women with diabetes mellitus: consensus opinion by the North American Menopause Society. Menopause 2000; 7: 87-95.
11. Godsland IF, Gangar K, Walton C et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846-853.
12. Akkad AA, Halligan AW, Abrams K & al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstetrics and Gynecology 1997; 89: 97-103.
13. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipids lipoproteins and apolioprotein(a) concentrations; analysis of studies published until 2000. Fertility and Sterility 2001; 75: 898-915.
14. Nappi RE, Cagnacci A, Granella F et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38: 157-163.
15. Reginster JY, Albert A, Deroisy R et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Eyorel) 50. Maturitas 1997; 27: 179-186.
16. Li C, Samsioe G, Lidfeldt J et al. A population based study of Swedish women. The women's Health in Lund Area (WHILA) study. Effects of norethisterone acetate addition to estradiol in long term HRT. Maturitas 2000; 36: 139-152.
17. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. New England journal of Medicine 2001; 344: 1743-1749.
18. Uhler ML, Marks JW, Voigt BJ & Judd HL. Comparison of the impact of transdermal versus oral estrogens on markers of gallstone formation in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1998; 83: 410-414.
19. Wollter-Svensson LO, Stadberg E, Andersson K et al. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstetricia et Gynecologica Scandinavica 1997; 76: 449-454.